Crossref
Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma
Oncology in Clinical Practice · 21.08.2024 · 20 (4) · 286-290
DOI: 10.5603/ocp.97707 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology in Clinical Practice, online erschienen am 21.08.2024. Verfasst von Agnieszka Chmielewska und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Chmielewska, A., & Kubiatowski, T. (2024). Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma. Oncology in Clinical Practice, 20(4), 286-290. https://doi.org/10.5603/ocp.97707
Vancouver
Chmielewska A, Kubiatowski T. Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma. Oncology in Clinical Practice. 2024;20(4):286-290. doi:10.5603/ocp.97707
BibTeX
@article{Chmielewska2024,
author = {Chmielewska, Agnieszka and Kubiatowski, Tomasz},
title = {Ivosidenib in the treatment of patients with IDH1 mutated cholangiocarcinoma},
journal = {Oncology in Clinical Practice},
year = {2024},
volume = {20},
number = {4},
pages = {286--290},
doi = {10.5603/ocp.97707}
}
EUVIMED